Adaptive therapy for perioperative non–small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment
Translational Oncology · 2026-02 · 64 · 102660
DOI: 10.1016/j.tranon.2025.102660 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Oncology, 2026-02. Verfasst von Li-Jin Xie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Cancer Treatment Center, The Second Affiliated Hospital of Hainan Medical University, 368 Yehai Road, Haikou, 57031…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Key Research and Development Project of Hainan Province, National Natural Science Foundation of China, Natural Science Foundation of Hainan Province.
Abstract (Originalsprache)
Lung cancer remains the leading cause of cancer incidence and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for about 85% of cases. The low rate of early diagnosis and the high rate of occult metastases limit the survival benefits of conventional treatments. The current TNM staging system fails to fully reflect tumor heterogeneity or the dynamic molecular evolution of the disease, thus affecting the prediction of recurrence and the prognostic stratification. Some recent advances in minimal residual disease (MRD) detection, such as ultra-sensitive liquid biopsy technologies, have largely overcome the limitations of traditional imaging and offered a transformative approach for continuous, precision-based management of lung cancer. This review systematically summarized the technological evolution of MRD detection and highlighted its clinical significance in guiding adaptive therapy for NSCLC, including treatment escalation, de-escalation, and the emerging concept of precision-guided drug holidays. Moreover, the authors comprehensively discussed the "Four-Dimensional TNMB Staging System," which incorporates continuous molecular monitoring to address the static limitations of conventional staging and enhance the accuracy of prognostic stratification. Although ongoing challenges, such as the lack of standardized interpretation criteria and limited detection sensitivity, the combinations with the third-generation liquid biopsy platforms, multi-omics analyses, and multi-center prospective validation studies are expected to advance the clinical implementation of MRD-guided strategies. The paradigm change will enable the transition of NSCLC management from conventional standardized models to a precision-guided, closed-loop system of "monitoring-intervention-remonitoring," establishing a solid theoretical and practical foundation for comprehensive, molecularly driven management strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Cancer Treatment Center, The Second Affiliated Hospital of Hainan Medical University, 368 Yehai Road, Haikou, 570311, China.
- Department of Oncology, Cancer Treatment Center, The Second Affiliated Hospital of Hainan Medical University, 368 Yehai Road, Haikou, 570311, China.
- Department of Radiation Oncology, Cancer Treatment Center, The Second Affiliated Hospital of Hainan Medical University, 368 Yehai Road, Haikou, 570311, China. Electronic address: wellyy2005@hainmc.edu.cn.
- Department of Oncology, Cancer Treatment Center, The Second Affiliated Hospital of Hainan Medical University, 368 Yehai Road, Haikou, 570311, China. Electronic address: twjlucky@163.com.
Förderung
- Key Research and Development Project of Hainan Province
- National Natural Science Foundation of China
- Natural Science Foundation of Hainan Province
- Hainan Provincial Department of Science and Technology
- Education Department of Hainan Province
- Hainan Medical University
Zitieren
APA
Xie, L. J., Fu, L. L., Liu, S. C., Bai, C. S., Xu, B. C., He, X. W., Lin, H. F., Zeng, Y. C., & Tang, W. J. (2026). Adaptive therapy for perioperative non–small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment. Translational Oncology, 64, 102660. https://doi.org/10.1016/j.tranon.2025.102660
Vancouver
Xie LJ, Fu LL, Liu SC, Bai CS, Xu BC, He XW, et al. Adaptive therapy for perioperative non–small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment. Translational Oncology. 2026;64:102660. doi:10.1016/j.tranon.2025.102660
BibTeX
@article{Xie2026,
author = {Xie, Li-Jin and Fu, Li-Li and Liu, Shu-Cen and Bai, Chang-Sen and Xu, Bai-Cheng and He, Xiong-Wen and Lin, Hai-Feng and Zeng, Yue-Can and Tang, Wen-Jun},
title = {Adaptive therapy for perioperative non–small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment},
journal = {Translational Oncology},
year = {2026},
volume = {64},
pages = {102660},
doi = {10.1016/j.tranon.2025.102660}
}
EUVIMED